CN104870470A - 人松驰素类似物、其药物组合物及其在医药上的应用 - Google Patents

人松驰素类似物、其药物组合物及其在医药上的应用 Download PDF

Info

Publication number
CN104870470A
CN104870470A CN201480003657.1A CN201480003657A CN104870470A CN 104870470 A CN104870470 A CN 104870470A CN 201480003657 A CN201480003657 A CN 201480003657A CN 104870470 A CN104870470 A CN 104870470A
Authority
CN
China
Prior art keywords
seq
chain
human relaxin
relaxin
recombinant human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201480003657.1A
Other languages
English (en)
Other versions
CN104870470B (zh
Inventor
张连山
刘佳建
曹国庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruishi Biomedical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN201480003657.1A priority Critical patent/CN104870470B/zh
Publication of CN104870470A publication Critical patent/CN104870470A/zh
Application granted granted Critical
Publication of CN104870470B publication Critical patent/CN104870470B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及人松驰素类似物、编码所述人松驰素类似物的多核苷酸、其药物组合物及其在医药上的应用，还公开了所述人松驰素类似物的衍生物。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201480003657.1A 2013-11-07 2014-10-10 人松驰素类似物、其药物组合物及其在医药上的应用 Active CN104870470B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201480003657.1A CN104870470B (zh) 2013-11-07 2014-10-10 人松驰素类似物、其药物组合物及其在医药上的应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2013105482218 2013-11-07
CN201310548221 2013-11-07
PCT/CN2014/088280 WO2015067113A1 (zh) 2013-11-07 2014-10-10 人松驰素类似物、其药物组合物及其在医药上的应用
CN201480003657.1A CN104870470B (zh) 2013-11-07 2014-10-10 人松驰素类似物、其药物组合物及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN104870470A true CN104870470A (zh) 2015-08-26
CN104870470B CN104870470B (zh) 2017-10-10

Family

ID=53040882

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480003657.1A Active CN104870470B (zh) 2013-11-07 2014-10-10 人松驰素类似物、其药物组合物及其在医药上的应用

Country Status (13)

Country Link
US (1) US20160326230A1 (zh)
EP (1) EP3067365A1 (zh)
JP (1) JP2016536306A (zh)
KR (1) KR20160071472A (zh)
CN (1) CN104870470B (zh)
AU (1) AU2014346141A1 (zh)
BR (1) BR112016009572A2 (zh)
CA (1) CA2928754A1 (zh)
HK (1) HK1211594A1 (zh)
MX (1) MX2016005545A (zh)
RU (1) RU2016117959A (zh)
TW (1) TW201518319A (zh)
WO (1) WO2015067113A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107007822A (zh) * 2016-01-27 2017-08-04 江苏恒瑞医药股份有限公司 一种含有重组人松弛素‑2类似物的药物组合物及其制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107417787B (zh) * 2016-05-23 2020-11-17 江苏恒瑞医药股份有限公司 一种人松弛素2类似物的制备方法
CN110637027A (zh) * 2017-02-08 2019-12-31 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
AU2020321977C1 (en) 2019-07-31 2024-04-18 Eli Lilly And Company Relaxin analogs and methods of using the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006075819A1 (en) * 2004-03-30 2006-07-20 Industry-Academic Cooperation Foundation, Yonsei University Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
WO2009140657A2 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of treating chronic heart failure
CN102180964A (zh) * 2011-03-16 2011-09-14 济南环肽医药科技有限公司 一种人类松弛素-2 Relaxin的固相合成方法
CN102603888A (zh) * 2012-04-11 2012-07-25 郭德军 一种人松弛素2前体及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006075819A1 (en) * 2004-03-30 2006-07-20 Industry-Academic Cooperation Foundation, Yonsei University Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
WO2009140657A2 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of treating chronic heart failure
CN102180964A (zh) * 2011-03-16 2011-09-14 济南环肽医药科技有限公司 一种人类松弛素-2 Relaxin的固相合成方法
CN102603888A (zh) * 2012-04-11 2012-07-25 郭德军 一种人松弛素2前体及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107007822A (zh) * 2016-01-27 2017-08-04 江苏恒瑞医药股份有限公司 一种含有重组人松弛素‑2类似物的药物组合物及其制备方法

Also Published As

Publication number Publication date
KR20160071472A (ko) 2016-06-21
RU2016117959A (ru) 2017-12-11
HK1211594A1 (zh) 2016-05-27
MX2016005545A (es) 2016-10-03
CN104870470B (zh) 2017-10-10
EP3067365A1 (en) 2016-09-14
WO2015067113A1 (zh) 2015-05-14
AU2014346141A1 (en) 2016-05-19
CA2928754A1 (en) 2015-05-14
US20160326230A1 (en) 2016-11-10
JP2016536306A (ja) 2016-11-24
BR112016009572A2 (pt) 2017-09-19
TW201518319A (zh) 2015-05-16

Similar Documents

Publication Publication Date Title
KR100984635B1 (ko) 티모신 β4 유도체 및 이의 용도
RU2764197C1 (ru) Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение
JP2024517995A (ja) 組換えｉ型ヒト化コラーゲンポリペプチド及びその製造方法並びに使用
MX2014009129A (es) Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15).
CN103923937B (zh) 一种可溶性表达人脑利钠肽重组蛋白的方法和应用
JPH05255392A (ja) Ａ−ｃ−ｂプロインスリン、その製造法および使用法、およびインスリン生産の中間体
CN113683679B (zh) 一种重组i型人源化胶原蛋白c1l6t及其制备方法和用途
CN104870470A (zh) 人松驰素类似物、其药物组合物及其在医药上的应用
EP2664622B1 (en) Polypeptides, nucleic acid molecule encoding polypeptides, and uses of polypeptides
JP2002504802A (ja) ウロコルチンペプチド
WO2018171535A1 (zh) 重组人胰岛素原融合蛋白及其制备方法和用途
CN114195875B (zh) 一种胎盘来源内源性多肽及其应用
CN114621327A (zh) GLP-1、GIP和Gcg多重受体激动蛋白质
AU2010294240B2 (en) PlGF-1 in homodimeric form
CN113956331A (zh) 异位子宫内膜识别多肽及其衍生物和应用
JP2007502841A (ja) 成長ホルモンの２０ｋＤａ胎盤性変種を用いる体形成療法

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211594

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20200110

Address after: 201210 Room 201 and 203, floor 2, building 1, No. 298, Xiangke Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Patentee after: Ruishi biomedical Co., Ltd

Address before: 200245 No. 279, Wen Jing Road, Shanghai, Minhang District

Co-patentee before: Hengrui Medicine Co., Ltd., Jiangsu Prov.

Patentee before: Hengrui Pharmaceutical Co., Ltd., Shanghai

TR01 Transfer of patent right
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1211594

Country of ref document: HK